A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
Clinical Trial
[키워드] 1:1
95% CI
95% confidence interval
adjusted hazard ratio
adolescents and adult
antiviral therapy
approved
assigned
Asymptomatic
Avigan
clearance
clinical
conducted
Cooperative
COVID-19
death
Disease progression
Endpoint
enrolled
Favipiravir
Fever
group
hospital
IMPROVE
in viral
Japan
late treatment group
Multicenter trial
occurred
Open-label
oral broad-spectrum inhibitor
Patient
performance status
primary endpoint
Prospective
Randomized
randomized clinical trial
Randomly
reduction in
regimen
Registered
registry
resolution of symptoms
reverse transcription-PCR
RNA-dependent RNA polymerase
RT-PCR
secondary endpoint
significantly
the patient
therapy
time to defervescence
transient hyperuricemia
Treatment
treatment group
treatment of influenza
viral clearance
with COVID-19
[DOI] 10.1128/AAC.01897-20 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1128/AAC.01897-20 PMC 바로가기 [Article Type] Clinical Trial